Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial.

Date publication

juin 2025

Journal

Lancet (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher

Tous les auteurs :
Rao S, Samalin-Scalzi E, Evesque L, Ben Abdelghani M, Morano F, Roy A, Dahan L, Tamberi S, Dhadda AS, Saunders MP, Casanova N, Guimbaud R, Lievre A, Maurel J, Fakih M, Tian C, Harrison J, Jones MM, Cornfeld M, Spano JP, Rochefort P,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40517007

Résumé

Retifanlimab has activity in programmed death ligand 1-positive advanced squamous cell anal carcinoma (SCAC) that has progressed on platinum chemotherapy. We aimed to prospectively assess the benefit of adding retifanlimab to initial carboplatin-paclitaxel for this disease.

Mots clés

Humans, Carboplatin, administration & dosage, Paclitaxel, administration & dosage, Male, Female, Middle Aged, Anus Neoplasms, drug therapy, Double-Blind Method, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Carcinoma, Squamous Cell, drug therapy, Neoplasm Recurrence, Local, drug therapy, Adult, Progression-Free Survival

Référence

Lancet. 2025 06 14;405(10495):2144-2152